Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Fibrillation

Financiado

Cerrado

The structure based design of a blocker of formation of amyloid fibers of the se...

The structure based design of a blocker of formation of amyloid fibers of the segment AADTWE in the mutant D38A of the protein transthyretin which causes familial amyloidosis Several neurodegenerative and systemic amyloid diseases are putatively caused by the formation of insoluble protein fibrils, which accumulate in human tissues and interfere with normal organ function. The amylome is the set of pro... ver más

31/05/2015

ETH Zürich

275K€

Presupuesto del proyecto: 275K€

Líder del proyecto

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-05-31 No tenemos la información de la convocatoria

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ETH Zürich

0.00€ | Lider

Proyectos interesantes

BIO2016-78310-R

Medical Technol...

Biotechnology

309K€ Cerrado

PDC2021-120914-I00

Medical Technol...

Biomedical Imag...

150K€ Cerrado

STAMYEV

Medical Technol...

Applied Physics

328K€ Cerrado

AMYLOIDINTERMEDIATE

Medical Technol...

Applied Physics

172K€ Cerrado

PGC2018-096335-B-I00

Medical Technol...

Applied Physics

168K€ Cerrado

PID2020-113907RA-I00

Medical Technol...

Biotechnology

109K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 275K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Several neurodegenerative and systemic amyloid diseases are putatively caused by the formation of insoluble protein fibrils, which accumulate in human tissues and interfere with normal organ function. The amylome is the set of proteins that are capable of forming amyloid-like fibrils, as consequence of the self-aggregation of some segments. The familial amyloidosis or FAP is a slowly progressive condition characterized by the buildup of abnormal deposits of transthyretin (TTR) in the body's organs. Most patients with FAP have early and severe impairment of the autonomious nervous system and also visual deterioration. A variant of TTR, presenting the D38A mutation, was detected in patients suffering from amyloidosis. Analysis performed by Eisenberg's team showed that the aspartic acid 38 is likely to be within a non self-aggregating segment in the native protein (ADDTWE). However, when this segment carries the mutation (AADTWE), it turns into a self-associating segment (not published). We hypothesize that this segment is the cause of the fibrillation of transthyretin for the D38A mutation and that disrupting packing of the fibril spine can hinder fibrillation. The goal of this proposal is the structure-based design of a blocker of aggregation of amyloid fibers of the segment AADTWE in the mutant TTR[D38A]. We will develop two different strategies for designing putative blockers of the aggregation of TTR: the structure-based design of an all D-peptide inhibitor and the construct of a chimeric protein between aggregation-inhibitor HET-S globular domain and the self-aggregating segment AADTWE. We will have to check the established inhibition model by X-ray crystallography and NMR techniques. Finally, inhibitors can be purchased commercially for synthesis of the designed fibril blockers. This project can be considered as a key in biomedical improvement, especially in neurodegenerative diseases, because it could bring us a way to stop the development of these illnesses.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores